Background and Purpose—The goal of this study was to examine the influence of
preexisting symptomatic atherosclerotic disease on subsequent ischemic event rates and …

Background Clopidogrel was superior to aspirin in patients with previous manifestations of
atherothrombotic disease in the CAPRIE study and its benefit was amplified in some high …

Background—Antiplatelet agents are widely recognized for their efficacy in reducing the
occurrence of vascular events in patients with atherothrombotic disease. Aspirin is currently …

Background: The CAPRIE study showed the superiority of clopidogrel over acetylsalicylic
acid (ASA) for reducing the combined risk of major atherothrombotic events in patients with …

Background Combination antiplatelet therapy with clopidogrel and aspirin may reduce the
rate of recurrent stroke during the first 3 months after a minor ischemic stroke or transient …

Background The Clopidogrel for High Atherothrombotic Risk and Ischaemic Stabilisation,
Management and Avoidance (CHARISMA) trial reported no statistically significant benefit of …

Aim. Though combination of clopidogrel added to aspirin has been compared to aspirin
alone in patients with stroke or transient ischemic attack, limited data exists on the relative …

Background and Purpose—In patients with acute ischemic stroke caused by large artery
atherosclerosis, clopidogrel plus aspirin versus aspirin alone might be more effective to …

Background—The Clopidogrel in High-risk patients with Acute Non-disabling
Cerebrovascular Events (CHANCE) trial showed that the combined treatment of clopidogrel …

BACKGROUND: Acute nondisabling cerebrovascular events are common and often portend
a disabling stroke. Aspirin is the only antiplatelet agent to have been studied in patients …